JOINT FILING AGREEMENTJoint Filing Agreement • November 20th, 2017 • Abrams Capital, LLC • Pharmaceutical preparations
This Joint Filing Agreement, dated as of November 20, 2017, is by and among Abrams Capital Partners II L.P., Abrams Capital LLC, Abrams Capital Management LLC, Abrams Capital Management L.P. and David Abrams (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G/A and/or 13D with respect to shares of Common Stock, $0.001 par value per share, of Keryx Biopharmaceuticals, Inc. that may be beneficially owned by them from time to time. Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G/A and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule. This Joint Filing Agreement may be terminated by any of the Filers upon one w
